BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
BioAge Labs, Inc.NASDAQ: BIOA
Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other non-current liabilities rises 391.8% from a year ago
Other non-current liabilities stood at $477K at the end of Q1 FY2026, up 391.8% from a year earlier and up 28.9% from the prior quarter. Over 3 fiscal years it compounded at -85.9% a year.
Context
- Other non-current liabilities amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other non-current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether other non-current liabilities keeps rising in the next quarterly balance sheet after a +391.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 370K USD
- Year-over-year change
- +137.2%
- 3-year CAGR
- -85.9%
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 370K | +137.2% |
| FY2024 | 2024-12-31 | 156K | -99.9% |
| FY2023 | 2023-12-31 | 132.95M | +0.1% |
| FY2022 | 2022-12-31 | 132.88M | — |
Other Non-current Liabilities vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +391.8% is the highest of 7, against a peer median of -67.2%.
- Other non-current liabilities amounts to 0.1% of total assets for BIOA, versus a peer median of 1.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $81.52M USD | — | — | 35.1% | |
| Mar 2026 | $19.27M USD | -79.4% | +4.3% | 17.4% | |
| Mar 2026 | $16.12M USD | +43.0% | +39.3% | 4.1% | |
| Mar 2026 | $13.17M USD | — | +309.6% | 13.3% | |
| Mar 2026 | CA$6.35M CAD | -25.2% | -48.7% | 0.6% | |
| Mar 2026 | CA$4.21M CAD | -92.1% | -61.1% | 0.7% | |
| Mar 2026 | $2.87M USD | -54.9% | — | 1.9% | |
BIOABioAge Labs, Inc. | Mar 2026 | $477K USD | +391.8% | -85.9% | 0.1% |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding BIOA) | — | -67.2% | +4.3% | 1.9% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.